Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Cash from Financing Activities for 13 consecutive years, with $12.1 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 3360.46% year-over-year to $12.1 million; the TTM value through Mar 2026 reached $88.2 million, up 1201.17%, while the annual FY2025 figure was $76.4 million, 87.52% down from the prior year.
  • Cash from Financing Activities hit $12.1 million in Q1 2026 for Viking Therapeutics, down from $75.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $606.0 million in Q1 2024 and bottomed at -$5.0 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $57.4 million, with a median of $1.0 million recorded in 2024.
  • Year-over-year, Cash from Financing Activities soared 22770.21% in 2022 and then crashed 840.0% in 2023.
  • Viking Therapeutics' Cash from Financing Activities stood at $10.7 million in 2022, then plummeted by 98.25% to $188000.0 in 2023, then skyrocketed by 431.91% to $1.0 million in 2024, then soared by 7410.3% to $75.1 million in 2025, then tumbled by 83.92% to $12.1 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $12.1 million, $75.1 million, and $480000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.